China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

Drug developer NextCure said on Monday it had signed a deal worth up to $745 million with China-based drugmaker Simcere Zaiming to develop a cancer therapy for solid tumors.

In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio. That is ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

Senators Bernie Sanders and Angus King are preparing to introduce legislation that would ban pharmaceutical companies from advertising prescription drugs directly to consumers, The Wall Street Journal ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

China has vowed to fight back over what it called “discriminatory restrictive measures” by the U.S. that it said are endangering an agreement hammered out between the two countries last month.

Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug ... billion deal with China’s ...

Twenty-seven states and the District of Columbia have filed a lawsuit in bankruptcy court seeking to block the sale of ...